levofloxacin has been researched along with rabeprazole in 26 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (rabeprazole) | Trials (rabeprazole) | Recent Studies (post-2010) (rabeprazole) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 1,073 | 446 | 405 |
| Protein | Taxonomy | levofloxacin (IC50) | rabeprazole (IC50) |
|---|---|---|---|
| Adenosine receptor A3 | Homo sapiens (human) | 3.219 | |
| Urease subunit alpha | Helicobacter pylori 26695 | 0.29 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 3.219 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 1.737 | |
| D(3) dopamine receptor | Homo sapiens (human) | 2.326 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 3.219 | |
| WD repeat-containing protein 5 | Homo sapiens (human) | 0.49 | |
| Urease subunit beta | Helicobacter pylori 26695 | 0.29 | |
| Histone-lysine N-methyltransferase 2A | Homo sapiens (human) | 0.49 | |
| NAD(+) hydrolase SARM1 | Homo sapiens (human) | 3.25 | |
| Cytosolic endo-beta-N-acetylglucosaminidase | Homo sapiens (human) | 4.47 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 8.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (57.69) | 29.6817 |
| 2010's | 10 (38.46) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Hibi, T; Muraoka, H; Nishizawa, T; Suzuki, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Arancio, F; Armuzzi, A; Cammarota, G; Cannizzaro, O; Cianci, R; Cuoco, L; Gasbarrini, A; Gasbarrini, G; Pirozzi, G; Santarelli, L; Zocco, MA | 1 |
| Chan, CK; Fung, FM; Gu, Q; Hu, WH; Lai, KC; Lam, SK; Wong, BC; Wong, WM; Xia, HH; Yee, YK; Yuen, MF | 1 |
| Angeletti, S; De Francesco, V; Hassan, C; Ierardi, E; Lorenzetti, R; Marignani, M; Morini, S; Zullo, A | 1 |
| Branca, G; Cammarota, G; Cannizzaro, O; Cesaro, P; Cianci, R; di Caro, S; Fedeli, P; Gasbarrini, G; Lecca, PG; Martino, A | 1 |
| Castro, LP; Cerqueira, MC; Cindr, JM; Coelho, LG; Gallo, MA; Mendonça, S; Moretzsohn, LD; Passos, MC; Pedrazzoli-Júnior, J; Ribeiro, ML; Vieira, WL; Vitiello, L | 1 |
| Bilardi, C; Dulbecco, P; Giannini, EG; Mamone, M; Mansi, C; Santi, ML; Savarino, V; Testa, R | 2 |
| Cannaviello, C; De Francesco, V; Efrati, C; Hassan, C; Ierardi, E; Maconi, G; Manes, G; Morini, S; Panella, C; Piglionica, D; Scaccianoce, G; Zullo, A | 1 |
| Hassan, C; Morini, S; Perna, F; Ricci, C; Vaira, D; Zullo, A | 1 |
| Chen, A; Hsu, PI; Lai, KH; Lo, GH; Lu, CY; Peng, NJ; Tsay, FW; Tseng, HH; Wu, DC; Yu, FJ | 1 |
| Coelho, L; Moretzsohn, L; Sanches, B; Vieira, G | 1 |
| Aydin, A; Musoglu, A; Oruc, N; Ozutemiz, O; Tuncyurek, M; Turan, I | 1 |
| Furuse, J; Itabashi, M; Iwamoto, N; Kitagawa, N; Konno, T; Miyazawa, T; Motoori, S; Saisho, H; Saito, S | 1 |
| Li, Y; Pan, X; Qian, B; Qiu, Y; Shi, R; Tang, Q; Yao, L; Zhang, G | 1 |
| Goh, KL; Manikam, J; Qua, CS | 1 |
| Ma, HJ; Wang, JL | 1 |
| Chen, MC; Hu, CT; Lei, WY; Lin, JS; Wu, DC; Yi, CH | 1 |
| Hong, SN; Kim, JJ; Lee, H; Lee, JH; Lee, YC; Min, BH; Rhee, PL | 1 |
| Akkan, T; Aktaş, B; Atbaşı, ST; Başyiğit, S; Nazlıgül, Y; Şimşek, G; Uzman, M; Yılmaz, B; Yüksel, O | 1 |
| Chen, YH; Hsu, PI; Hu, HM; Kuo, CH; Kuo, FC; Su, WW; Wang, SSW; Wu, DC; Wu, IC; Wu, TS | 1 |
| Hsu, PI; Kao, J; Lin, MH; Shie, CB; Tsay, FW; Wang, JW; Wu, DC; Wu, IT | 1 |
1 review(s) available for levofloxacin and rabeprazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
14 trial(s) available for levofloxacin and rabeprazole
| Article | Year |
|---|---|
Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Female; Follow-Up Studies; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Penicillins; Prospective Studies; Rabeprazole; Tinidazole | 2000 |
Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Rabeprazole; Rifabutin; Treatment Outcome | 2003 |
High-dose versus low-dose clarithromycin in 1-week triple therapy, including rabeprazole and levofloxacin, for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Omeprazole; Rabeprazole; Treatment Outcome | 2004 |
A study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Infective Agents; Antitrichomonal Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Pilot Projects; Rabeprazole; Time Factors; Tinidazole; Treatment Outcome | 2006 |
Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Benzimidazoles; Breath Tests; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Ofloxacin; Omeprazole; Pilot Projects; Rabeprazole; Tinidazole; Treatment Outcome | 2006 |
Helicobacter pylori eradication with either quadruple regimen with lactoferrin or levofloxacin-based triple therapy: a multicentre study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lactoferrin; Levofloxacin; Male; Middle Aged; Ofloxacin; Rabeprazole; Tinidazole; Treatment Outcome | 2007 |
Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Retreatment | 2007 |
Failure of Helicobacter pylori treatment after regimes containing clarithromycin: new practical therapeutic options.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Doxycycline; Female; Furazolidone; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Organometallic Compounds; Prospective Studies; Rabeprazole; Treatment Failure; Treatment Outcome; Urea | 2008 |
The modified sequential treatment regimen containing levofloxacin for Helicobacter pylori eradication in Turkey.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Drug Administration Schedule; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Prospective Studies; Rabeprazole; Treatment Outcome; Turkey; Young Adult | 2009 |
Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Ch
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Asian People; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Proton Pump Inhibitors; Rabeprazole | 2010 |
Levofloxacin-amoxicillin/clavulanate-rabeprazole versus a standard seven-day triple therapy for eradication of Helicobacter pylori infection.
Topics: Amoxicillin; Clavulanic Acid; Drug Combinations; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Rabeprazole | 2014 |
Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Rabeprazole; Republic of Korea; Treatment Outcome; Urea | 2015 |
The impact of amalgam dental fillings on the frequency of Helicobacter pylori infection and H. pylori eradication rates in patients treated with concomitant, quadruple, and levofloxacin-based therapies.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Dental Amalgam; Dental Restoration, Permanent; Disease Eradication; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Levofloxacin; Male; Metronidazole; Middle Aged; Outpatients; Prospective Studies; Rabeprazole; Tetracycline; Treatment Outcome; Turkey; Urea | 2015 |
Comparison of 10-day levofloxacin bismuth-based quadruple therapy and levofloxacin-based triple therapy for Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Disk Diffusion Antimicrobial Tests; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Medication Adherence; Middle Aged; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Retreatment | 2017 |
11 other study(ies) available for levofloxacin and rabeprazole
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation.
Topics: Anti-Infective Agents; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Helicobacter pylori; Mutation | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Endoscopy, Digestive System; Female; Glossitis; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Penicillins; Prospective Studies; Rabeprazole; Treatment Outcome; Urea | 2003 |
New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents; Benzimidazoles; Drug Combinations; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Pilot Projects; Rabeprazole; Treatment Outcome | 2005 |
Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Chi-Square Distribution; Cytochrome P-450 CYP2C19; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Organometallic Compounds; Patient Selection; Polymorphism, Genetic; Prospective Studies; Rabeprazole; Salvage Therapy; Treatment Outcome | 2008 |
[A case of mucosa-associated lymphoid tissue lymphoma with penicillin allergy successfully treated with levofloxacin, minomycin and rabeprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Biopsy; Drug Hypersensitivity; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Minocycline; Ofloxacin; Penicillins; Rabeprazole | 2010 |
High-dose rabeprazole-amoxicillin dual therapy and rabeprazole triple therapy with amoxicillin and levofloxacin for 2 weeks as first and second line rescue therapies for Helicobacter pylori treatment failures.
Topics: Amoxicillin; Anti-Bacterial Agents; Breath Tests; Drug Therapy, Combination; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Treatment Failure; Treatment Outcome; Urea | 2012 |
Quadruple therapy for eradication of Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Chi-Square Distribution; Drug Therapy, Combination; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Proton Pump Inhibitors; Rabeprazole; Time Factors; Treatment Outcome; Young Adult | 2013 |
The efficacy of culture-guided versus empirical therapy with high-dose proton pump inhibitor as third-line treatment of Helicobacter pylori infection: A real-world clinical experience.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Proton Pump Inhibitors; Rabeprazole; Tetracycline; Treatment Outcome | 2022 |